Emcure Pharmaceuticals (NSE:EMCURE) Debt-to-Equity: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:EMCURE Emcure Pharmaceuticals Ltd NSE:EMCURE
42 GF Score
Price ₹2,003.80
! 4 Warning Signs
View Full Analysis

What is Emcure Pharmaceuticals Debt-to-Equity?

Emcure Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹ Mil. Emcure Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹ Mil. Emcure Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2026 was ₹ Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Emcure Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

NSE:EMCURE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.23   Med: 0.79   Max: 1.12
Current: 0.31

During the past 12 years, the highest Debt-to-Equity Ratio of Emcure Pharmaceuticals was 1.12. The lowest was 0.23. And the median was 0.79.

NSE:EMCURE's Debt-to-Equity is ranked worse than
54.05% of 814 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs NSE:EMCURE: 0.31

Emcure Pharmaceuticals  (NSE:EMCURE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Emcure Pharmaceuticals Debt-to-Equity Related Terms

Emcure Pharmaceuticals Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Emcure Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emcure Pharmaceuticals Debt-to-Equity Chart

Emcure Pharmaceuticals Annual Data
Trend Mar10 Mar11 Mar12 Mar19 Mar20 Mar21 Mar23 Mar24 Mar25 Mar26
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.04 0.88 0.74 0.22 0.31

Emcure Pharmaceuticals Quarterly Data
Dec12 Jun23 Sep23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.34 - 0.31 -

NSE:EMCURE vs ZTS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emcure Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emcure Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emcure Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Emcure Pharmaceuticals's Debt-to-Equity falls into.


NSE:EMCURE
42GF Score
Emcure Pharmaceuticals Ltd NSE:EMCURE
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emcure Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Emcure Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(10049.83 + 5144.91) / 49500.32
=0.31

Emcure Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=( + ) /
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emcure Pharmaceuticals Business Description

Other Exchanges 544210:India
Address Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune, MH, IND, 411 057
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
42GF Score

Get the complete analysis for NSE:EMCURE

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,003.80
Price